Innate Pharma IPHA
NASDAQ IPHA
$1.59 +0.05 (+3.25%)
As of: Nov 11, 2026 · 3:56 PM EST

Innate Pharma (IPHA) Cash from Financing Activities (2019)

Updated

Innate Pharma (IPHA) posted Cash from Financing Activities of $6.86 million for the year ended Dec 31, 2025, compared with -$6.5 million a year earlier.

Analysis

Innate Pharma (IPHA) Cash from Financing Activities (2019) Analysis & Trends

Since the year ended Dec 31, 2017, Innate Pharma has reported Cash from Financing Activities for 9 years.

  • The figure for the year ended Dec 31, 2025 stands as the highest annual Cash from Financing Activities since the year ended Dec 31, 2021.
  • Business Quant data shows IPHA's Cash from Financing Activities at -$6.5 million in the year ended Dec 31, 2024, -$2.13 million in the year ended Dec 31, 2023, -$1.93 million in the year ended Dec 31, 2022 and $30.68 million in the year ended Dec 31, 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -7.22 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -8.53 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 6.82 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -2.43 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 6.63 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -4.39 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -1.53 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -2.51 Bn
10 Innate Pharma 142.45 Mn -64.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 -867,449.38
API Access

Innate Pharma Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=IPHA&period=max&api_key=YOUR_API_KEY